3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 77 points (-0.4%) at 17,034 as of Tuesday, Sept. 9, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 824 issues advancing vs. 2,132 declining with 162 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Teva Pharmaceutical Industries ( TEVA), down 2.0%, Alexion Pharmaceuticals ( ALXN), down 1.6%, Vertex Pharmaceuticals ( VRTX), down 1.3%, Amgen ( AMGN), down 0.8% and Eli Lilly and ( LLY), down 0.7%. A company within the industry that increased today was AbbVie ( ABBV), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biogen Idec is down $2.98 (-0.9%) to $328.32 on light volume. Thus far, 338,309 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $327.53-$330.74 after having opened the day at $330.74 as compared to the previous trading day's close of $331.31.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $78.0 billion and is part of the health care sector. Shares are up 18.5% year-to-date as of the close of trading on Monday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Celgene ( CELG) is down $1.05 (-1.1%) to $92.98 on light volume. Thus far, 1.4 million shares of Celgene exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $92.55-$94.00 after having opened the day at $93.72 as compared to the previous trading day's close of $94.03.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $75.0 billion and is part of the health care sector. Shares are up 11.3% year-to-date as of the close of trading on Monday. Currently there are 18 analysts that rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.22 (-0.7%) to $29.18 on light volume. Thus far, 7.6 million shares of Pfizer exchanged hands as compared to its average daily volume of 22.9 million shares. The stock has ranged in price between $29.14-$29.44 after having opened the day at $29.39 as compared to the previous trading day's close of $29.40.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $188.0 billion and is part of the health care sector. Shares are down 4.0% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

China Trade Truce, General Electric and Tesla - 5 Things You Must Know

China Trade Truce, General Electric and Tesla - 5 Things You Must Know